BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 27127303)

  • 21. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL.
    Benson MJ; Dillon SR; Castigli E; Geha RS; Xu S; Lam KP; Noelle RJ
    J Immunol; 2008 Mar; 180(6):3655-9. PubMed ID: 18322170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
    Tai YT; Cho SF; Anderson KC
    Front Immunol; 2018; 9():1822. PubMed ID: 30147691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
    Lee L; Bounds D; Paterson J; Herledan G; Sully K; Seestaller-Wehr LM; Fieles WE; Tunstead J; McCahon L; Germaschewski FM; Mayes PA; Craigen JL; Rodriguez-Justo M; Yong KL
    Br J Haematol; 2016 Sep; 174(6):911-22. PubMed ID: 27313079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. APRIL and BAFF proteins increase proliferation of human adipose-derived stem cells through activation of Erk1/2 MAP kinase.
    Zonca M; Mancheño-Corvo P; DelaRosa O; Mañes S; Büscher D; Lombardo E; Planelles L
    Tissue Eng Part A; 2012 Apr; 18(7-8):852-9. PubMed ID: 22059379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
    Tai YT; Chang BY; Kong SY; Fulciniti M; Yang G; Calle Y; Hu Y; Lin J; Zhao JJ; Cagnetta A; Cea M; Sellitto MA; Zhong MY; Wang Q; Acharya C; Carrasco DR; Buggy JJ; Elias L; Treon SP; Matsui W; Richardson P; Munshi NC; Anderson KC
    Blood; 2012 Aug; 120(9):1877-87. PubMed ID: 22689860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
    Sanchez E; Gillespie A; Tang G; Ferros M; Harutyunyan NM; Vardanyan S; Gottlieb J; Li M; Wang CS; Chen H; Berenson JR
    Clin Cancer Res; 2016 Jul; 22(13):3383-97. PubMed ID: 26960399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression.
    Gowda PS; Wildman BJ; Trotter TN; Xu X; Hao X; Hassan MQ; Yang Y
    Mol Cancer Res; 2018 Jul; 16(7):1138-1148. PubMed ID: 29592898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. APRIL binding to BCMA activates a JNK2-FOXO3-GADD45 pathway and induces a G2/M cell growth arrest in liver cells.
    Notas G; Alexaki VI; Kampa M; Pelekanou V; Charalampopoulos I; Sabour-Alaoui S; Pediaditakis I; Dessirier V; Gravanis A; Stathopoulos EN; Tsapis A; Castanas E
    J Immunol; 2012 Nov; 189(10):4748-58. PubMed ID: 23071284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TACI-dependent APRIL signaling maintains autoreactive B cells in a mouse model of systemic lupus erythematosus.
    Tran NL; Schneider P; Santiago-Raber ML
    Eur J Immunol; 2017 Apr; 47(4):713-723. PubMed ID: 28267197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas.
    Guadagnoli M; Kimberley FC; Phan U; Cameron K; Vink PM; Rodermond H; Eldering E; Kater AP; van Eenennaam H; Medema JP
    Blood; 2011 Jun; 117(25):6856-65. PubMed ID: 21543761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
    Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
    Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow.
    Matthes T; Manfroi B; Zeller A; Dunand-Sauthier I; Bogen B; Huard B
    Leukemia; 2015 Sep; 29(9):1882-90. PubMed ID: 26159051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
    Tai YT; Anderson KC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
    [No Abstract]   [Full Text] [Related]  

  • 36. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.
    Moreaux J; Sprynski AC; Dillon SR; Mahtouk K; Jourdan M; Ythier A; Moine P; Robert N; Jourdan E; Rossi JF; Klein B
    Eur J Haematol; 2009 Aug; 83(2):119-29. PubMed ID: 19456850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
    Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
    Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways.
    Shen X; Guo Y; Qi J; Shi W; Wu X; Ju S
    Cell Biochem Funct; 2016 Mar; 34(2):104-10. PubMed ID: 26914861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
    Hipp S; Tai YT; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam PJ; Anderson KC; Friedrich M
    Leukemia; 2017 Aug; 31(8):1743-1751. PubMed ID: 28025583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma.
    Oden F; Marino SF; Brand J; Scheu S; Kriegel C; Olal D; Takvorian A; Westermann J; Yilmaz B; Hinz M; Daumke O; Höpken UE; Müller G; Lipp M
    Mol Oncol; 2015 Aug; 9(7):1348-58. PubMed ID: 25953704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.